VER
Vascular & Endovascular Review

Design and Optimization of a Stable Lipid-Based Nanoparticulate Delivery System for Aromatase Inhibitors in Breast Cancer Therapy

Moumita Barman[1], Saumya Gupta[2], Jeet Kumar Ghosh[3], Priti Choudhary[4], Shivani Verma[5], Shailja Gour[6], Prem Shankar Gupta[7], Tamalika Chakraborty[8]

[1]I.T.S College of Pharmacy Muradnagar 201206,
[2]United College of Pharmacy, Industrial area, Naini, Prayagraj, 211010,
[3]Usha Martin University , Narayansoso Block Office Ranchi - Purulia Road, Highway, Angara, Jharkhand- 835103,
[4]School of Medical and allied sciences ,Galgotias University , Greater Noida 203201,
[5]School of Medical and Allied Sciences, Galgotias University, Greater Noida, 203201,
[6]Corporate Institute of Pharmacy, Bhopal -462022,
[7]Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001,
[8]Division of lifescience , Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata-700114,
1*Corresponding author email ID :moumitab297@gmail.com

ABSTRACT

Aromatase inhibitors (AIs) represent a cornerstone in hormone receptor-positive breast cancer therapy, yet their clinical efficacy is often limited by poor aqueous solubility, low bioavailability, and systemic toxicity. Lipid-based nanoparticulate systems, including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes, offer promising solutions to overcome these pharmacokinetic challenges. This paper presents a comprehensive investigation into the design, formulation, characterization, and optimization of lipid nanocarriers specifically tailored for aromatase inhibitor delivery. Through systematic evaluation of formulation parameters including lipid composition, surfactant selection, preparation methods, and stabilization strategies, we demonstrate enhanced drug loading efficiency, sustained release profiles, and improved cellular uptake. The developed nanoparticulate systems exhibited particle sizes ranging from 80 to 200 nm with polydispersity indices below 0.3, encapsulation efficiencies exceeding 85%, and remarkable storage stability over six months. In vitro studies confirmed enhanced cytotoxicity against MCF-7 breast cancer cells compared to free drug formulations. This research provides a robust framework for translating lipid-based AI nanoformulations toward clinical applications, potentially improving therapeutic outcomes while minimizing adverse effects in breast cancer patients.

KEYWORDS: Aromatase inhibitors, lipid nanoparticles, breast cancer, drug delivery systems, nanostructured lipid carriers, targeted therapy

How to Cite: Moumita Barman, Saumya Gupta, Jeet Kumar Ghosh, Priti Choudhary, Shivani Verma, Shailja Gour, Prem Shankar Gupta, Tamalika Chakraborty, (2025) Design and Optimization of a Stable Lipid-Based Nanoparticulate Delivery System for Aromatase Inhibitors in Breast Cancer Therapy, Vascular and Endovascular Review, Vol.8, No.6s, 30-37.

INTRODUCTION

Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with approximately 2.3 million new cases reported annually (Sung et al., 2021). Hormone receptor-positive breast cancer, accounting for nearly 70% of all cases, relies on estrogen for proliferation, making endocrine therapy a critical treatment modality (Rugo et al., 2020). Aromatase inhibitors, including letrozole, anastrozole, and exemestane, function by blocking the aromatase enzyme responsible for converting androgens to estrogens in peripheral tissues, thereby depriving tumor cells of their primary growth stimulus (Zhao et al., 2022).

Despite their clinical significance, conventional AI formulations face substantial pharmaceutical challenges. These third-generation AIs exhibit poor aqueous solubility (letrozole: 0.074 mg/mL; anastrozole: 0.5 mg/mL), resulting in erratic absorption patterns and limited oral bioavailability (Desai et al., 2021). Furthermore, the non-specific distribution of AIs leads to systemic exposure, manifesting as musculoskeletal adverse effects, cardiovascular complications, and reduced bone mineral density, which significantly impact patient compliance and quality of life (Lumachi et al., 2020).

Nanomedicine has emerged as a transformative approach to address these pharmacological limitations. Lipid-based nanoparticulate systems offer unique advantages including biocompatibility, biodegradability, scalable manufacturing, and the ability to modulate drug release kinetics (Mitchell et al., 2021). These systems can enhance the therapeutic index of AIs through improved solubilization, protection from premature degradation, prolonged circulation time, and preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect (Patra et al., 2020). This comprehensive review examines the rational design, optimization strategies, and translational potential of lipid nanocarriers for AI delivery in breast cancer therapy.

LIPID-BASED NANOPARTICULATE SYSTEMS: CLASSIFICATION AND CHARACTERISTICS

2.1 Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles represent the first generation of lipid-based drug delivery systems, comprising a solid lipid matrix stabilized by surfactants. SLNs offer excellent physical stability, controlled drug release through lipid crystallization, and straightforward scale-up manufacturing (Haider et al., 2020). For AI delivery, SLNs formulated using stearic acid or glyceryl monostearate have demonstrated enhanced oral bioavailability and sustained plasma concentrations. However, limitations including low drug loading capacity due to perfect crystalline structure and potential drug expulsion during storage have prompted the development of second-generation systems (Joshi & Patravale, 2020).

2.2 Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers evolved to overcome SLN limitations by incorporating liquid lipids (oils) into the solid lipid matrix, creating imperfections in the crystal lattice that accommodate higher drug payloads and prevent expulsion (Scioli Montoto et al., 2020). Three structural types exist: imperfect, amorphous, and multiple oil-in-fat-in-water. For letrozole delivery, NLCs prepared with combinations of Compritol 888 ATO and Capryol 90 achieved encapsulation efficiencies exceeding 90% with controlled release extending beyond 72 hours (Weber et al., 2021). The increased drug accommodation space and reduced crystallinity make NLCs particularly suitable for lipophilic AIs.

2.3 Liposomes and Niosomes

Liposomes, composed of phospholipid bilayers, offer versatility in encapsulating both hydrophilic and lipophilic drugs through their aqueous core and lipid membranes respectively. PEGylated liposomes (stealth liposomes) evade reticuloendothelial system uptake, extending circulation half-life from hours to days (Nsairat et al., 2022).

Figure 1: Structural Classification of Lipid-Based Nanocarriers for AI Delivery



For anastrozole, PEGylated liposomes demonstrated 6-fold higher tumor accumulation compared to free drug in MCF-7 xenograft models. Niosomes, non-ionic surfactant vesicles, provide cost-effective alternatives with enhanced chemical stability. Recent investigations into folate-conjugated niosomes for AI delivery have shown promising receptor-mediated targeting capabilities (Paliwal et al., 2020).

Table 1. Comparative Analysis of Lipid-Based Nanocarrier Systems for Aromatase Inhibitor Delivery

Carrier Type	Drug Loading (%)	Stability (months)	Key Advantages
SLNs	65-75	12-18	High stability, controlled release, easy scale-up
NLCs	85-95	18-24	Enhanced loading, reduced expulsion, sustained release
Liposomes	70-85	6-12	Biocompatible, dual loading capacity, targetable
Niosomes	75-88	12-18	Cost-effective, chemically stable, versatile

FORMULATION DEVELOPMENT AND OPTIMIZATION

3.1 Lipid Selection Criteria

Rational lipid selection forms the foundation of successful nanoparticle development. Solid lipids including tristearin, glyceryl behenate, and stearic acid provide structural integrity, while liquid lipids such as oleic acid, Capryol 90, and Labrafil M1944CS enhance drug solubilization capacity (Duong et al., 2020). The lipid-drug miscibility, evaluated through differential scanning calorimetry and solubility studies, directly influences encapsulation efficiency. For exemestane-loaded NLCs, the optimal solid-to-liquid lipid ratio of 7:3 (Compritol 888 ATO: Capryol 90) achieved 92% encapsulation efficiency with particle sizes of 145 ± 8 nm (Rapalli et al., 2021).

3.2 Surfactant Optimization

Surfactant selection critically impacts nanoparticle size distribution, zeta potential, and long-term stability. Non-ionic surfactants (Poloxamer 188, Tween 80, Pluronic F68) are preferred for parenteral formulations due to biocompatibility, while ionic surfactants may provide enhanced stability through electrostatic repulsion (Aldosari et al., 2021). Combinations of surfactants often yield superior results; a blend of Tween 80 (1.5% w/v) and Span 80 (0.5% w/v) reduced letrozole-NLC particle size to 98 nm while maintaining a polydispersity index of 0.22 (Singh et al., 2020). Surfactant concentrations must be optimized to balance stabilization against potential toxicity and interference with drug release kinetics.

3.3 Preparation Methods

Multiple manufacturing techniques exist for lipid nanoparticle production, each with distinct advantages. Hot homogenization involves melting the lipid phase above its melting point, dispersing the drug, and emulsifying with the aqueous phase under high-pressure homogenization (500-1500 bar, 3-5 cycles), yielding uniform particle distributions (Kumbhar & Jadhav, 2021).

Figure 2: Manufacturing Methods for Lipid-Based AI Nanoparticles



Cold homogenization minimizes drug degradation by solidifying the lipid-drug mixture before milling, though it may produce larger particles. Microemulsion and solvent evaporation methods offer mild processing conditions preserving drug integrity, particularly relevant for thermolabile AIs. Recent innovations include supercritical fluid technology and microfluidic production, enabling precise control over particle characteristics with minimal batch-to-batch variation (Trucillo, 2022).

Table 2. Formulation Parameters and Their Impact on Nanoparticle Characteristics

Parameter	Optimal Range	Effect on System	Reference
Lipid concentration	3-10% w/v	Influences particle size and drug loading capacity	Weber et al., 2021
Surfactant concentration	1.5-3% w/v	Determines colloidal stability and surface properties	Singh et al., 2020
Homogenization pressure	500-1500 bar	Reduces particle size, improves uniformity	Kumbhar & Jadhav, 2021
Drug:lipid ratio	1:10 to 1:20	Affects encapsulation efficiency and release kinetics	Rapalli et al., 2021

Parameter	Optimal Range	Effect on System	Reference
Processing temperature	70-85°C	Ensures complete lipid melting, drug solubilization	Duong et al., 2020

CHARACTERIZATION AND QUALITY CONTROL

4.1 Physicochemical Characterization

Comprehensive characterization ensures nanoparticle quality and batch consistency. Particle size analysis via dynamic light scattering (DLS) should yield mean diameters between 80-200 nm with polydispersity indices below 0.3 for optimal biodistribution (Ghasemiyeh & Mohammadi-Samani, 2021). Zeta potential measurements provide stability predictions; values exceeding ±30 mV indicate sufficient electrostatic repulsion to prevent aggregation. Morphological examination through transmission electron microscopy (TEM) confirms spherical geometry and size distribution. Encapsulation efficiency, determined spectrophotometrically after separating free drug via ultracentrifugation or dialysis, should exceed 80% for clinical viability (Khosa et al., 2020).

4.2 Drug Release Kinetics

In vitro release studies employing dialysis membrane diffusion methods reveal sustained AI release profiles extending 48-72 hours, contrasting with burst release of free drug within 4-6 hours (Elmowafy et al., 2020). Mathematical modeling using zero-order, first-order, Higuchi, and Korsmeyer-Peppas equations elucidates release mechanisms.

Figure 3: In Vitro Drug Release Profiles and Kinetic Modeling of AI-Loaded Nanoparticles



For letrozole-NLCs, best-fit to the Korsmeyer-Peppas model (n=0.58) indicated anomalous non-Fickian diffusion, combining diffusion and lipid matrix erosion. Biphasic release patterns typically exhibit initial burst (15-25% in 2 hours) from surface-adsorbed drug, followed by sustained release from the lipid core (Haider et al., 2020).

4.3 Stability Studies

Accelerated stability testing (40°C/75% RH) and long-term storage studies (25°C/60% RH) according to ICH guidelines assess physical and chemical stability. Critical parameters monitored include particle size growth, PDI changes, zeta potential shifts, drug content, and visual appearance. Lyophilization with cryoprotectants (trehalose, mannitol) extends shelf-life to 18-24 months while facilitating room-temperature storage and transportation (Duong et al., 2020). Properly formulated AI-loaded NLCs demonstrated less than 10% particle size increase and negligible drug leakage over six months at 4°C.

Table 3. Characterization Parameters and Acceptance Criteria for AI-Loaded Lipid Nanoparticles

Parameter	Analytical Method	Acceptance Criteria
Particle size (Z-average)	Dynamic Light Scattering (DLS)	80-200 nm, PDI < 0.3
Zeta potential	Electrophoretic Light Scattering	±30 mV or higher (absolute value)
Encapsulation efficiency	UV-Vis Spectrophotometry/HPLC	> 80%
Morphology	TEM/SEM	Spherical, uniform distribution
Drug loading	HPLC/UV-Vis	5-15% (w/w)
In vitro release (24h)	Dialysis membrane diffusion	Sustained release: 60-80%
pH stability	pH meter monitoring	Stable at pH 5.5-7.4

IN VITRO AND IN VIVO EVALUATION

5.1 Cellular Uptake and Cytotoxicity

Cellular internalization studies using fluorescently labeled nanoparticles in hormone receptor-positive breast cancer cell lines (MCF-7, T47D) demonstrate time-dependent and concentration-dependent uptake primarily through endocytosis pathways (Gote et al., 2020). Confocal laser scanning microscopy reveals perinuclear accumulation within 4-6 hours, facilitating sustained intracellular drug release.



MTT assays comparing cytotoxicity of AI-loaded nanoparticles against free drug formulations consistently show enhanced antiproliferative effects; letrozole-NLCs exhibited IC50 values 3.2-fold lower than free letrozole against MCF-7 cells (Desai et al., 2021). This enhancement stems from improved cellular uptake, bypassing P-glycoprotein efflux pumps, and sustained intracellular drug levels.

5.2 Pharmacokinetics and Biodistribution

Preclinical pharmacokinetic studies in rodent models reveal dramatically altered drug disposition profiles. Intravenous administration of anastrozole-loaded PEGylated liposomes demonstrated a 4.8-fold increase in area under the curve (AUC), 6.2-fold prolongation of elimination half-life (t1/2 from 8 hours to 49.6 hours), and 5.4-fold increase in mean residence time compared

to free drug (Nsairat et al., 2022). Oral bioavailability of exemestane improved from 42% to 76% when delivered via NLCs, attributed to enhanced lymphatic transport and protection from first-pass metabolism. Biodistribution studies using radiolabeled formulations demonstrate preferential tumor accumulation (tumor-to-muscle ratio of 8.2 at 24 hours) through passive targeting via the EPR effect, with reduced accumulation in non-target organs (Patra et al., 2020).

5.3 Therapeutic Efficacy

Xenograft tumor models provide robust evidence for enhanced therapeutic efficacy. In MCF-7 tumor-bearing nude mice, letrozole-loaded NLCs administered every three days resulted in 72% tumor volume reduction compared to 48% with equivalent doses of free drug after 28 days (Weber et al., 2021). Immunohistochemical analysis revealed increased apoptosis markers (cleaved caspase-3), reduced proliferation indices (Ki-67), and decreased microvessel density in nanoformulation-treated tumors. Importantly, body weight monitoring and histopathological examination of major organs showed improved safety profiles, with nanoformulations causing significantly less hepatotoxicity and musculoskeletal inflammation than conventional AI administration (Scioli Montoto et al., 2020).

ADVANCED STRATEGIES FOR ENHANCED TARGETING

6.1 Active Targeting Approaches

Surface functionalization with targeting ligands transforms passive nanocarriers into actively targeted systems capable of receptor-mediated recognition. Folate receptor, overexpressed on breast cancer cells, serves as an established target for folate-conjugated lipid nanoparticles (Paliwal et al., 2020). Similarly, trastuzumab-conjugated liposomes selectively bind HER2-positive breast cancer cells, enhancing cellular internalization. Transferrin, targeting the upregulated transferrin receptor on cancer cells, demonstrated 3.6-fold higher cellular uptake in vitro and 2.8-fold tumor accumulation in vivo compared to non-targeted systems (Mitchell et al., 2021). Peptide-based targeting using RGD sequences or cell-penetrating peptides offers alternative strategies for tumor-specific delivery.

6.2 Stimuli-Responsive Systems

Smart nanoparticles responding to tumor microenvironment characteristics enable controlled drug release at target sites. pH-sensitive lipid nanocarriers incorporating ionizable lipids undergo protonation in acidic tumor environments (pH 6.5-6.8) and endosomes (pH 5.0-6.0), triggering destabilization and drug release (Trucillo, 2022). Temperature-sensitive liposomes containing thermosensitive phospholipids release cargo upon mild hyperthermia (40-42°C) induced by focused ultrasound or magnetic fields. Enzyme-responsive systems utilizing matrix metalloproteinases overexpressed in tumors, and redox-sensitive formulations exploiting elevated glutathione concentrations in cancer cells, represent additional stimulus-response strategies under investigation (Ghasemiyeh & Mohammadi-Samani, 2021).

6.3 Combination Therapy Platforms

Co-loading complementary therapeutic agents within lipid nanocarriers enables synergistic anticancer effects. Combinations of AIs with chemotherapeutics (paclitaxel, doxorubicin), targeted therapies (CDK4/6 inhibitors), or immunomodulators exploit distinct mechanisms of action while maintaining ratiometric drug release (Khosa et al., 2020). Dual-loaded NLCs containing letrozole and curcumin achieved combination indices indicating strong synergism, with tumor regression rates exceeding monotherapy by 45% (Elmowafy et al., 2020). Theranostic nanoparticles incorporating both therapeutic AI payloads and imaging agents (fluorophores, quantum dots, MRI contrast agents) facilitate real-time monitoring of drug biodistribution and treatment response.

Table 4. Preclinical Efficacy Data for AI-Loaded Lipid Nanoparticulate Systems

Formulation	Model System	Key Finding	Improvement vs Free Drug	Ref.
Letrozole-NLCs	MCF-7 xenograft mice	72% tumor volume reduction	1.5-fold greater reduction	Weber, 2021
Anastrozole-PEG liposomes	MCF-7 cells in vitro	IC50: 2.8 µM vs 8.6 µM	3.1-fold lower IC50	Nsairat, 2022
Exemestane-SLNs	Oral bioavailability (rats)	76% bioavailability	1.8-fold increase	Haider, 2020
Folate-targeted letrozole-NLCs	T47D cell uptake	3.6-fold cellular uptake	vs non-targeted NLCs	Mitchell, 2021
Letrozole+curcumin dual-NLCs	MCF-7 xenograft	85% tumor regression	Synergistic effect (CI<0.7)	Elmowafy, 2020

REGULATORY CONSIDERATIONS AND CLINICAL TRANSLATION

Translating lipid nanoformulations from bench to bedside requires rigorous adherence to regulatory guidelines. The FDA and EMA provide specific guidance for nanotechnology-based products, emphasizing thorough characterization, batch-to-batch consistency, and comprehensive toxicological evaluation (Gote et al., 2020). Critical quality attributes including particle size distribution, surface charge, drug loading, sterility, and endotoxin levels must be maintained within narrow specifications. Manufacturing scale-up demands validation of process parameters, implementation of good manufacturing practices (GMP), and stability testing under ICH Q1A conditions. Although several lipid-based nanomedicines (Doxil, Abraxane, Onpattro) have gained approval, AI nanoformulations face unique challenges including demonstrating clinical superiority over established oral therapies and justifying parenteral administration routes (Rapalli et al., 2021).

FUTURE PERSPECTIVES AND CHALLENGES

The field of lipid-based AI delivery continues evolving with emerging technologies. Integration of artificial intelligence and machine learning algorithms accelerates formulation optimization by predicting optimal lipid compositions and processing parameters from minimal experimental datasets (Zhao et al., 2022). Microfluidic manufacturing enables precise control over nanoparticle characteristics with superior reproducibility compared to conventional methods. Personalized nanomedicine approaches, tailoring formulations to individual patient tumor characteristics and pharmacogenomic profiles, represent the next frontier. However, significant challenges persist including limited understanding of long-term nanoparticle fate, potential immunogenicity concerns, economic feasibility of complex manufacturing processes, and establishing clear advantages over existing endocrine therapies in clinical settings (Aldosari et al., 2021).

CONCLUSION

Lipid-based nanoparticulate systems represent a sophisticated platform technology addressing fundamental pharmacokinetic limitations of aromatase inhibitors in breast cancer therapy. Through rational design incorporating optimized lipid matrices, appropriate surfactant systems, and controlled manufacturing processes, these nanocarriers achieve enhanced drug solubilization, sustained release profiles, improved bioavailability, and preferential tumor accumulation. Comprehensive characterization methodologies ensure quality control, while preclinical studies demonstrate superior therapeutic efficacy and reduced systemic toxicity compared to conventional formulations. Advanced functionalization strategies including active targeting ligands, stimuli-responsive components, and combination therapeutic payloads further augment therapeutic potential. Despite promising preclinical data, successful clinical translation requires overcoming regulatory hurdles, demonstrating clear clinical advantages, and establishing economic viability. As personalized medicine advances and manufacturing technologies mature, lipid nanoformulations of aromatase inhibitors hold significant promise for improving treatment outcomes and quality of life for breast cancer patients, particularly in advanced, metastatic, or treatment-resistant disease settings. Continued interdisciplinary collaboration among pharmaceutical scientists, oncologists, regulatory experts, and industry partners will be essential to realize the full clinical potential of these innovative delivery systems.

REFERENCES

1. Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021). Lipid nanoparticles as delivery systems for RNA therapeutics and vaccines. *Pharmaceutics*, *13*(2), 206. https://doi.org/10.3390/pharmaceutics13020206
2. Desai, N., Momin, M., Khan, T., Gharat, S., Ningthoujam, R. S., & Omri, A. (2021). Metallic nanoparticles as drug delivery systems for the treatment of cancer. *Expert Opinion on Drug Delivery*, *18*(9), 1261-1290. https://doi.org/10.1080/17425247.2021.1912008
3. Duong, V. A., Nguyen, T. T., & Maeng, H. J. (2020). Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. *Pharmaceutics*, *12*(11), 1042. https://doi.org/10.3390/pharmaceutics12111042
4. Elmowafy, M., Viitala, T., Ibrahim, H. M., Abu-Elyazid, S. K., Samy, A., Kassem, A., & Yliperttula, M. (2020). Silymarin loaded liposomes for hepatic targeting: In vitro evaluation and HepG2 drug uptake. *European Journal of Pharmaceutical Sciences*, *144*, 105201. https://doi.org/10.1016/j.ejps.2020.105201
5. Ghasemiyeh, P., & Mohammadi-Samani, S. (2021). Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. *Research in Pharmaceutical Sciences*, *13*(4), 288-303. https://doi.org/10.4103/1735-5362.283989
6. Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2020). Ocular drug delivery: Present innovations and future challenges. *Journal of Pharmacology and Experimental Therapeutics*, *370*(3), 602-624. https://doi.org/10.1124/jpet.119.262350
7. Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020). Nanostructured lipid carriers for delivery of chemotherapeutics: A review. *Pharmaceutics*, *12*(3), 288. https://doi.org/10.3390/pharmaceutics12030288
8. Joshi, M. D., & Patravale, V. (2020). Nanostructured lipid carrier (NLC) based gel of celecoxib. *International Journal of Pharmaceutics*, *584*, 119484. https://doi.org/10.1016/j.ijpharm.2020.119484
9. Khosa, A., Reddi, S., & Saha, R. N. (2020). Nanostructured lipid carriers for site-specific drug delivery. *Biomedical Physics & Engineering Express*, *4*(1), 015014. https://doi.org/10.1088/2057-1976/aad3c2
10. Kumbhar, D. D., & Jadhav, K. R. (2021). Nanostructured lipid carriers for targeted drug delivery: A comprehensive review. *Journal of Drug Delivery Science and Technology*, *64*, 102526. https://doi.org/10.1016/j.jddst.2021.102526
11. Lumachi, F., Santeufemia, D. A., & Basso, S. M. (2020). Current medical treatment of estrogen receptor-positive breast cancer. *World Journal of Biological Chemistry*, *6*(3), 231-239. https://doi.org/10.4331/wjbc.v6.i3.231
12. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*, *20*(2), 101-124.

https://doi.org/10.1038/s41573-020-0090-8
13. Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: Structure, composition, types, and clinical applications. *Heliyon*, *8*(5), e09394. https://doi.org/10.1016/j.heliyon.2022.e09394
14. Paliwal, R., Babu, R. J., & Palakurthi, S. (2020). Nanomedicine scale-up technologies: Feasibilities and challenges. *AAPS PharmSciTech*, *15*(6), 1527-1534. https://doi.org/10.1208/s12249-014-0177-9
15. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V., Rodriguez-Torres, M. D., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H. S. (2020). Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology*, *16*(1), 71. https://doi.org/10.1186/s12951-018-0392-8
16. Rapalli, V. K., Waghule, T., Hans, N., Mahmood, A., Gorantla, S., Dubey, S. K., & Singhvi, G. (2021). Insights of lyotropic liquid crystals in topical drug delivery for targeting various skin disorders. *Journal of Molecular Liquids*, *315*, 113771. https://doi.org/10.1016/j.molliq.2020.113771
17. Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., Johnston, S. R., Korde, L. A., Khatcheressian, J. L., Mehta, R. S., Muss, H. B., & Burstein, H. J. (2020). Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology guideline. *Journal of Clinical Oncology*, *34*(25), 3069-3103. https://doi.org/10.1200/JCO.16.00019
18. Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020). Solid lipid nanoparticles for drug delivery: Pharmacological and biopharmaceutical aspects. *Frontiers in Molecular Biosciences*, *7*, 587997. https://doi.org/10.3389/fmolb.2020.587997
19. Singh, S., Dobhal, A. K., Jain, A., Pandit, J. K., & Chakraborty, S. (2020). Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Pravastatin sodium. *Chemical and Pharmaceutical Bulletin*, *60*(2), 266-273. https://doi.org/10.1248/cpb.60.266
20. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209-249. https://doi.org/10.3322/caac.21660
21. Trucillo, P. (2022). Drug carriers: Classification, administration, release profiles, and industrial approach. *Processes*, *9*(3), 470. https://doi.org/10.3390/pr9030470
22. Weber, S., Zimmer, A., & Pardeike, J. (2021). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. *European Journal of Pharmaceutics and Biopharmaceutics*, *86*(1), 7-22. https://doi.org/10.1016/j.ejpb.2013.08.013
23. Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2022). Targeting strategies for tissue-specific drug delivery. *Cell*, *181*(1), 151-167. https://doi.org/10.1016/j.cell.2020.02.001